Last update Dec. 24, 2022

Brivudine

Low Risk

Possibly safe. Probably compatible. Mild risk possible. Follow up recommended. Read the Comment.

It is a nucleoside analogue effective in vitro against herpes simplex virus type 1 and varicella-zoster virus. Used in treatment of Herpes zoster and herpes simplex. Oral and topical administration.

At latest update, relevant published data on excretion into breast milk were not found.

Because a high distribution volume (DV) and high protein-binding capacity, excretion into breast milk in significant amount is very unlikely.

Its low oral bioavailability impairs the pass of it from the mother's milk to the infant's plasma, except in prematures or in the early neonatal period, when a higher intestinal absorption may occur.

Until more data on this medication is available, safer alternative drugs are preferred, especially in such critical age periods.


See below the information of these related products:

Alternatives

Suggestions made at e-lactancia are done by APILAM team of health professionals, and are based on updated scientific publications. It is not intended to replace the relationship you have with your doctor but to compound it. The pharmaceutical industry contraindicates breastfeeding, mistakenly and without scientific reasons, in most of the drug data sheets.

Jose Maria Paricio, Founder & President of APILAM/e-Lactancia

Your contribution is essential for this service to continue to exist. We need the generosity of people like you who believe in the benefits of breastfeeding.

Thank you for helping to protect and promote breastfeeding.

José María Paricio, founder of e-lactancia.

Other names

Brivudine is also known as


Brivudine in other languages or writings:

Group

Brivudine belongs to this group or family:

Tradenames

Main tradenames from several countries containing Brivudine in its composition:

Pharmacokinetics

Variable Value Unit
Oral Bioavail. 30 %
Molecular weight 333 daltons
Protein Binding > 95 %
VD 1 l/Kg
pKa 9.74 -
Tmax 1 hours
16 hours

References

  1. McDonald EM, de Kock J, Ram FS. Antivirals for management of herpes zoster including ophthalmicus: a systematic review of high-quality randomized controlled trials. Antivir Ther. 2012 Abstract
  2. AEMPS. Brivudina. Ficha técnica. 2010 Full text (in our servers)
  3. Wassilew S; Collaborative Brivudin PHN Study Group. Brivudin compared with famciclovir in the treatment of herpes zoster: effects in acute disease and chronic pain in immunocompetent patients. A randomized, double-blind, multinational study. J Eur Acad Dermatol Venereol. 2005 Abstract
  4. Keam SJ, Chapman TM, Figgitt DP. Brivudin (bromovinyl deoxyuridine). Drugs. 2004 Abstract
  5. Rabasseda X. Brivudine: a herpes virostatic with rapid antiviral activity and once-daily dosing. Drugs Today (Barc). 2003 Abstract

Total visits

9,851

Help us improve this entry

How to cite this entry

Do you need more information or did not found what you were looking for?

   Write us at elactancia.org@gmail.com

e-lactancia is a resource recommended by El Parto Es Nuestro of Spain

Would you like to recommend the use of e-lactancia? Write to us at corporate mail of APILAM